Hong Kong Stock Market: China Biopharmaceuticals (01177.HK) Surges Over 3% Goldman Sachs Indicates That the Introduction of Bepirovirsen Therapy Could Upgrade the Company's Hepatitis Product Portfolio.

According to the WiseFinance APP, China Biopharmaceuticals (01177.HK) rose by over 3%, as of the time of writing, it had risen by 2.65%, to 5.81 Hong Kong dollars, with a turnover of 357 million Hong Kong dollars.